Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 9, 2024
Daily News
July 9, 2024
- Mounjaro Winner in May GP Rep Promotion Rankings: Intage
July 9, 2024
- PMDA to Push Simultaneous Development of Pediatric Drugs via New Consultation Center
July 9, 2024
- Moderna Medical Chief Voices Excitement for Flu-COVID Jab; Japan PIII Set to Kick Off by Year’s End
July 9, 2024
- LDP Group Renews Call for Gender-Neutral HPV Vaccination
July 9, 2024
- Shionogi Rolls Out In Vitro Diagnostic for Fetroja in Japan
July 9, 2024
- Rapalimus Granules Now Available in Japan: Nobelpharma
July 9, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…